WO2000004917A3 - USE OF HC gp-39 IN IMMUNE DISEASES - Google Patents

USE OF HC gp-39 IN IMMUNE DISEASES Download PDF

Info

Publication number
WO2000004917A3
WO2000004917A3 PCT/EP1999/005331 EP9905331W WO0004917A3 WO 2000004917 A3 WO2000004917 A3 WO 2000004917A3 EP 9905331 W EP9905331 W EP 9905331W WO 0004917 A3 WO0004917 A3 WO 0004917A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune diseases
present
lymphocytes
antigens
modulate
Prior art date
Application number
PCT/EP1999/005331
Other languages
French (fr)
Other versions
WO2000004917A9 (en
WO2000004917A2 (en
Inventor
Andreas Martinus Ma Miltenburg
Anna Maria Helena Boots
Original Assignee
Akzo Nobel Nv
Andreas Martinus Ma Miltenburg
Anna Maria Helena Boots
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv, Andreas Martinus Ma Miltenburg, Anna Maria Helena Boots filed Critical Akzo Nobel Nv
Priority to AU52875/99A priority Critical patent/AU5287599A/en
Priority to EP99938340A priority patent/EP1100526A2/en
Priority to JP2000560910A priority patent/JP2002521344A/en
Publication of WO2000004917A2 publication Critical patent/WO2000004917A2/en
Publication of WO2000004917A3 publication Critical patent/WO2000004917A3/en
Publication of WO2000004917A9 publication Critical patent/WO2000004917A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to the use of HC gp-39 to prevent inflammatory diseases. More specifically, HC gp-39 or fragments thereof can be used to modulate the reactivity of lymphocytes which are reactive to antigens other than HC gp-39 but which are present in the same tissue as where HC gp-39 is being expressed.
PCT/EP1999/005331 1998-07-23 1999-07-19 USE OF HC gp-39 IN IMMUNE DISEASES WO2000004917A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU52875/99A AU5287599A (en) 1998-07-23 1999-07-19 Use of hc gp-39 in immune diseases
EP99938340A EP1100526A2 (en) 1998-07-23 1999-07-19 USE OF HC gp-39 IN IMMUNE DISEASES
JP2000560910A JP2002521344A (en) 1998-07-23 1999-07-19 Use of HCgp-39 in immune diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98202471 1998-07-23
EP98202471.3 1998-07-23

Publications (3)

Publication Number Publication Date
WO2000004917A2 WO2000004917A2 (en) 2000-02-03
WO2000004917A3 true WO2000004917A3 (en) 2000-07-20
WO2000004917A9 WO2000004917A9 (en) 2000-08-24

Family

ID=8233962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/005331 WO2000004917A2 (en) 1998-07-23 1999-07-19 USE OF HC gp-39 IN IMMUNE DISEASES

Country Status (4)

Country Link
EP (1) EP1100526A2 (en)
JP (1) JP2002521344A (en)
AU (1) AU5287599A (en)
WO (1) WO2000004917A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400659A3 (en) 2001-07-24 2005-06-28 Zhu Zhou Woodbridge Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013517A1 (en) * 1994-10-27 1996-05-09 Akzo Nobel N.V. Novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
WO1997040149A1 (en) * 1996-04-18 1997-10-30 Akzo Nobel N.V. Autoantigen and proteins structurally related thereto for use in immunotherapy of autoimmune diseases
EP0805206A2 (en) * 1996-05-03 1997-11-05 Smithkline Beecham Corporation Human cartilage glycoprotein
EP0823478A2 (en) * 1996-08-09 1998-02-11 Smithkline Beecham Corporation Human cartilage gp 39-like gene

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013517A1 (en) * 1994-10-27 1996-05-09 Akzo Nobel N.V. Novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
WO1997040149A1 (en) * 1996-04-18 1997-10-30 Akzo Nobel N.V. Autoantigen and proteins structurally related thereto for use in immunotherapy of autoimmune diseases
EP0805206A2 (en) * 1996-05-03 1997-11-05 Smithkline Beecham Corporation Human cartilage glycoprotein
EP0823478A2 (en) * 1996-08-09 1998-02-11 Smithkline Beecham Corporation Human cartilage gp 39-like gene

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COENEN DE ROO C J J ET AL: "Human cartilage GP-39 induces and modifies a chronic relapsing arthritis in mice.", 62ND NATIONAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY AND THE 33RD NATIONAL SCIENTIFIC MEETING OF THE ASSOCIATION OF RHEUMATOLOGY HEALTH PROFESSIONALS;SAN DIEGO, CALIFORNIA, USA; NOVEMBER 8-12, 1998, vol. 41, no. 9 SUPPL., 1998, Arthritis & Rheumatism Sept., 1998, pages S214, XP002133815, ISSN: 0004-3591 *
VERHEIJDEN G F ET AL: "Human cartilage glycoprotein -39 as a candidate autoantigen in rheumatoid arthritis.", ARTHRITIS AND RHEUMATISM, (1997 JUN) 40 (6) 1115-25, XP002089334 *

Also Published As

Publication number Publication date
WO2000004917A9 (en) 2000-08-24
EP1100526A2 (en) 2001-05-23
AU5287599A (en) 2000-02-14
WO2000004917A2 (en) 2000-02-03
JP2002521344A (en) 2002-07-16

Similar Documents

Publication Publication Date Title
AU1321500A (en) Virtual dressing over the internet
AU5526399A (en) Improvements in or relating to the treatment of lesions
AU7722600A (en) Compositions and methods for the diagnosis and treatment of immune disorders
AU1597795A (en) Method of enhancing the human immune system
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
WO2001044489A3 (en) Galactomannan oligosaccharides and methods for the production and use thereof
HK1028568A1 (en) Alpha-ketoamide multicatalytic protease inhibitors
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
WO1999040083A3 (en) Bifunctional tryptase inhibitors
AU3025795A (en) Compositions which are suitable for employment as antidotes to blood anticoagulants, and their use
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
AU4364897A (en) Improvements in or relating to the prophylaxis of breast cancer
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
AU1908395A (en) Antibodies to mammalian natural killer antigens and uses
WO2000004917A3 (en) USE OF HC gp-39 IN IMMUNE DISEASES
EP2280071A3 (en) Haemophilus influenzae antigens and corresponding DNA fragments
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
WO1996016170A3 (en) Proteins involved in the regulation of cell-cell adhesion and uses thereof
AU6841300A (en) Human antibodies or fragments thereof binding to hla-cw6
AU3444499A (en) Monoclonal antibody 3-6-a specific to surface of dendritic cells among the peripheral blood leukocytes
AU2548597A (en) Antibodies against avirulence/pathogenicity proteins of plant pathogens
AU2593597A (en) Compositions for the diagnosis and treatment of chediak-higashi syndrome
AU7693198A (en) Processor interfacing to memory-centric computing engine
AU4020597A (en) Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of papillary renal cell carcinoma
WO1998030593A3 (en) Assay of histidine decarboxylase to detect cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 1999938340

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 560910

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09744282

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999938340

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999938340

Country of ref document: EP